The US approval lists the thyroid C cell cancers medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia type 2 (MEN 2) as contraindications because other GLP-1 agonists are known to cause such cancers in rodents.<unk>  causes immunogenicity in rodents, so its cancer risk could not be assessed. The European approval mentions the uncertainty about C cell cancers, but not as a contraindication.
Albiglutide
Semaglutide
Teduglutide
Dulaglutide
Liraglutide
Linagliptin
Saxagliptin
Exenatide